Kadans welcomes AviaoBio to Docklands Life Sciences Hub

Gene therapy medical solutions company AviadoBio is moving into the London Innovation Centre following the recent completion of their wet-lab Innovation Centre at levels four and five at 20 Water Street. It will be joining a growing European ecosystem of over 450 tenants that have been welcomed by developers Kadans Science Partner to the new docklands centre, including Cytiva, Akamis Bio, GeneFirst and Sherlock Bioscience.

Lisa Deschamps, CEO of AviadoBio, said: “We are very excited about our new partnership with Kadans and our laboratory and office space in the Innovation Centre at Canary Wharf. A state-of-the-art space allows us to more comfortably accommodate our growing team who is focused on developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Additionally, the accessibility to others in the life science space further supports our company's culture and focus on nurturing breakthrough discoveries.” 

Claudia Tripp, Commercial Asset Manager at Kadans Science Partner, said: “Attracting AviadoBio to the Innovation Centre so soon after its opening underscores both the level of demand for flexible, high quality wet lab facilities and high quality of the product we have delivered at 20 Water Street. It is also an illustration of the strong momentum we continue to generate in creating a go-to destination for health and life sciences organisations of all sizes at Canary Wharf. This facility also allows us to further strengthen our relationship with AviadoBio as we look to provide much needed space for start-up and early-stage companies who can subsequently grow with us at Canary Wharf.”

The Innovation Centre comprises 40,000 sq ft of fully fitted, flexible, wet-labs, ranging from bespoke 250 sq ft to over 2,000 sq ft labs, with tenants having the option of renting a bench in a shared lab, or taking their own private lab. 

AviadoBio joins a host of life sciences and healthcare organisations already based at Canary Wharf, including government-owned genomic health pioneer, Genomics England, Barts Health NHS Trust, Medicines and Healthcare products Regulatory Agency, Medical Defence Union, General Pharmaceutical Council and NHS Transformation. 

In tandem with the growth of the life sciences community at Canary Wharf, Kadans and Canary Wharf Group are progressing their joint venture to develop an 823,000 sq ft GIA commercial health and life sciences building, the largest in Europe, on the 3.3-hectare North Quay site, which is expected to be complete in 2027.

More information online